

2019 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Raleigh, NC – May 4, 2019

Conference Location **Marriott Raleigh City Center** **Phone: (919) 833-1120**
500 Fayetteville St. <https://www.marriott.com/hotels/travel/rdumc-raleigh-marriott-city-center>
Raleigh, NC 27601

Parking at the Conference Reduced parking for all participants is available for \$12.
Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk

Driving Directions from RDU **Take I-40E toward Raleigh.** Exit at the S Saunders St. exit - 298B toward downtown. Merge onto S Saunders, 401 N. Continue on 401 N. and turn right onto Lenoir St. The parking garage will be on left entrance side of the hotel off Lenoir St

Seminar Agenda and Syllabus Information Registration and breakfast begin at **7:30 a.m.** in the **Congressional Ballroom.** Please check signage for any last minute room changes.
The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions Case Study 1 – Cirrhosis and Encephalopathy
9:20 am	Hepatocellular Carcinoma <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology

	<ul style="list-style-type: none"> • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:25 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals
1:00 pm	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
2:15 pm	Break & View Exhibits
2:25 pm	NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:25 pm	Post-test and Wrap-Up <ul style="list-style-type: none"> • Adjourn at 3:40pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your
Seminar
Faculty**



A. SIDNEY BARRITT, IV, MD, MSCR, FACGA

Sidney Barritt received his medical degree from University of Virginia School of Medicine in Charlottesville after graduating with a BA in History from the University of Virginia. Later, Dr Barritt continued his education studying Epidemiology and receiving a Master's of Science in Clinical Research degree at the Gillings School of Global Public Health, University of North Carolina-Chapel Hill.

Dr. Barritt is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Barritt is interested in non-alcoholic fatty liver disease and liver transplant outcomes research. He participates in clinical and diagnostic trials and collaborates with research partners in the UNC school of Pharmacy and School of Public Health.



ANDREW JOSEPH MUIR, MD, MHS, FAASLD, AGAF

Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. He has particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

Dr. Muir attended medical school at Duke University. He went on to complete his internal medicine residency and gastroenterology fellowship at Duke, and he also served as chief resident at the Durham Veterans Administration Medical Center. Dr. Muir joined the faculty in the Division of Gastroenterology at Duke in 2000 and assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010



ELIZABETH K. GOACHER, PA-C

Elizabeth K Goacher is a Physician Assistant Specialist in Durham, North Carolina. She graduated with honors from Duke University School Of Medicine in 1998. Having more than 19 years of diverse experiences, especially in treating patients with liver and other GI diseases.

She is affiliated with many hospitals including Duke University Hospital, Duke Health Raleigh Hospital, Duke Regional Hospital, and cooperates with other doctors and specialists in medical group Private Diagnostic Clinic.
